Company Overview and News

2
Rubius IPO: A Bit Expensive And At An Early Stage

2018-07-11 seekingalpha
Rubius is still at an early stage. A new investigational drug application will be filed in the first quarter of 2019 and INDs for additional product candidates will be filed.
SYBX PFZ AGLE NVS 500680 PFE PFIZER ERYP ALNY

0
Arbutus Biopharma: Run Up Continues, Catalyst In Focus

2018-07-09 seekingalpha
PDUFA date for Alnylam Pharmaceuticals´ patisiran on August 11th is a near-term catalyst to look forward to (incorporates Arbutus´ LNP RNAi delivery technology).
ABUS ALNY

2
Regulus Stock Plunges on Cash Concerns Despite Restructuring

2018-07-09 zacks
Regulus Therapeutics Inc.’s (RGLS - Free Report) shares plunged 52% on Jul 6 following the announcement of drastic restructuring initiatives to extend its cash runway. Although the plans announced are expected to save $20 million annually and support the company’s operations till mid-2019, investors remain skeptical about the company’s cash position and are wary of its pipeline progress.
RGLS IONS CVRR ALNY SNY

29
Top 10 Stories of the First Half of 2018

2018-07-06 biospace
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
NKTR REGN CELGZ JUNO CELG HZNP ALNY

67
Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion

2018-07-02 zacks
Sanofi (SNY - Free Report) announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has issued a positive opinion recommending approval of Cablivi (caplacizumab). A marketing authorization application (“MAA”) is seeking approval of the candidate for the treatment of patients experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder.
BIIB ALNY SNY

22
Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation

2018-06-29 seekingalpha
RNA-based therapeutics are novel molecules aiming to stop the synthesis of rogue proteins at the ribonucleic acid (“RNA”) level. The market potential for RNA-based medicine is vast.
IONS AKCA ALNY

55
Medicines Company's Inclisiran Studies to Continue Unmodified

2018-06-28 zacks
The Medicines Company (MDCO - Free Report) announced that Independent Data Monitoring Committee (IDMC) has recommended that the ongoing phase III studies (ORION) of its candidate, inclisiran, will continue as designed and conducted, without modification. The IDMC’s recommendation was based on its planned review of unblinded safety and efficacy data from the trials.
ANIP GM.WS.A AGLE GM.WS.B GM.WS.C MDCO GM GM.WSB ALNY

126
Sarepta Pharma Pushes Two Biotech ETFs to New Highs

2018-06-20 zacks
Sarepta Therapeutics Inc. (SRPT - Free Report) was a star performer in Tuesday’s trading session, as the stock skyrocketed as much as 57.7% to a new high of $176.50 but closed a little lower, rising 36.8% (read: 4 Sector ETFs That Crushed S&P 500 in 9-Year Bull Run). The surge propelled the company’s market cap from $6.9 billion to more than $9 billion, making it the fifth most valuable drugmaker headquartered in Massachusetts, behind Biogen (BIIB - Free Report) , Vertex Pharmaceuticals (VRTX - Free Report) , Alexion Pharmaceuticals (ALXN - Free Report) and Alnylam Pharmaceuticals (ALNY - Free Report) .
SBIO VRTX ALXN BIIB SLDB SRPT IBB ALNY

39
PointState Capital Boosts The Medicines Company Stake

2018-06-12 marketfolly
Zach Schreiber's hedge fund firm PointState Capital has filed a 13G with the SEC regarding its position in The Medicines Co (MDCO). Per the filing, PointState now owns 5.3% of the company with over 3.87 million shares. This is up from the 3.7 million shares they owned at the end of the first quarter. The filing was made due to portfolio activity on June 1st. Per Yahoo Finance, The Medicines Company is "a biopharmaceutical company, provides medicines to treat acute and intensive care patients.
SYMQY MDCO SCLN ALNY 4582

73
Alnylam Pharmaceuticals Continues To Develop Options Outside Of Amyloidosis

2018-06-12 seekingalpha
Alnylam shares continue to trade below fair value, but investors should appreciate the risks that accompany pre-commercial biotechs.
BIIB PFE ALNY

39
Alnylam Reports Positive Data on Lumasiran in Renal Disease

2018-06-11 zacks
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced new positive results from its phase I/II study on its experimental RNAi therapeutic candidate, lumasiran, which targets glycolate oxidase (GO). The data was presented at the OxalEurope, European Hyperoxaluria Consortium, in Naples, Italy.
CHJHF CHA MDCO 0728 ALNY SNY

17
ALNY / Alnylam Pharmaceuticals, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - null (Passive Investment)

2018-06-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ALNYLAM PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 02043Q107 (CUSIP NUMBER) May 31, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
ALNY

17
ALNY / Alnylam Pharmaceuticals, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - null (Passive Investment)

2018-06-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ALNYLAM PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 02043Q107 (CUSIP NUMBER) May 31, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
ALNY

161
Your Daily Pharma Scoop: Zealand Dips, Eloxx Surges, Venetoclax Approved

2018-06-11 seekingalpha
Zealand Pharma (ZEAL) is a small Danish company that specializes in gastroenteric and metabolic diseases. The company has late-stage clinical programs with glepaglutide and three dasiglucagon product candidates. They also have a late-stage program in Phase 3 development and two Phase 3-ready programs, all with potential to launch into major markets: glepaglutide, a long-acting GLP-2 analog for short bowel syndrome, and dasiglucagon, a soluble, stable glucagon analog in liquid formulation in development as three distinct clinical programs.
AZN NVO AZN ZEAL ELOX ABBV CAH DRNA ABBV ALNY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ALNY / Alnylam Pharmaceuticals, Inc. on message board site Silicon Investor.

Alnylam Pharmaceuticals, Inc. (ALNY)
CUSIP: 02043Q107